Preliminary Line-Up of Presenters Set for 3rd Annual Stem Cell Summit

* Reuters is not responsible for the content in this press release.

Tue Jan 15, 2008 8:30am EST

Largest Gathering of Stem Cell Company Executives, Scientists, Investors and
Physicians on Feb. 26 in New York City

PHILADELPHIA, Jan. 15 /PRNewswire/ -- RRY Publications today announced the
preliminary line-up of presenters for the 3rd Annual Stem Cell Summit, which
is slated to bring together the largest gathering of stem cell company
executives, scientists, investors and physicians in New York City.
Participants will learn about the investment opportunities in the stem cell
marketplace, the groundbreaking stem cell products physicians are using today
and the growing market potential in terms of revenues.
    The 3rd Annual Stem Cell Summit will take place on Feb. 26, 2008, at the
Hilton New York.  Companies and products featured will include executives
from:

    3DM, Inc.                             MG Biotherapeutics, LLC
    Aastrom Biosciences, Inc.             Neuronyx, Inc.
    Aldagen, Inc.                         Novocell, Inc.
    AllCells, LLC                         Orthofix International, N.V.
    Arteriocyte, Inc.                     Osiris Therapeutics, Inc.
    Athersys, Inc.                        PrimeGen Biotech LLC
    BioE Corp.                            Progenitor Cell Therapy, LLC
    Bioheart, Inc.                        Regenetech, Inc.
    CellGenix Technologie Transfer GmbH   ReNeuron Group plc
    Cognate BioServices, Inc.             SpineSmith Partners LP
    Cytori Therapeutics, Inc.             StemCyte, Inc.
    Gamida Cell Ltd.                      Stemina, Inc.
    Genzyme Corp.                         TiGenix NV
    Geron Corp.                           Tissue Genesis, Inc.
    Harvest Technologies Corp.            Transition Therapeutics Inc.
    INCELL Corp. LLC                      TriStem Corp.
    MaxCyte, Inc.                         ViaCell, Inc.
    MesoBlast Limited                     VistaGen Therapeutics, Inc.


    In addition to the company and product overviews, Robin Young, president
of RRY Publications and the organizer of the annual Stem Cell Summit, will
provide an update on the 10-year market forecast for the industry.  A lunch
panel of patients who have been treated with stem cells will discuss how the
use of stem cell products changed their lives.
    "2008 is a year of major developments and advancements in stem cell
therapies," said Robin Young.  "We expect to see the industry generating $100
million in revenue from stem cell product sales in 2008."
                3rd Annual Stem Cell Summit Facts at a Glance

    What:        Largest Gathering of Stem Cell Company Executives,
                 Scientists, Investors and Physicians

    When:        Feb. 26, 2008

    Where:       Hilton New York
                 Trianon Ballroom
                 1335 Avenue of the Americas

    Who:         The Stem Cell Summit is organized by RRY Publications

    Admission:   $1,200 advance registration by Jan. 31, 2008
                 $1,500 at the door

    Information: For more information on presentation or sponsorship
opportunities, call Lisa Carpenter at 877-817-6450 or send an e-mail to
lisa@ryortho.com.  Additional information, including attendee registration
details, is available at www.stemcellsummit.com.
    Sponsors:  SpineSmith Partners LP
               Orthofix International, N.V.
               Blackstone Medical
               Aastrom Biosciences, Inc.
               Cytori Therapeutics, Inc.
               Regenetech, Inc.
               StemCyte, Inc.
               TiGenix NV
               Progenitor Cell Therapy, LLC
               New York City Bioscience Initiative

    Contacts:  Wendy Lau
               Russo Partners, LLC
               212-845-4272
               wendy.lau@russopartnersllc.com

SOURCE  RRY Publications

Wendy Lau of Russo Partners, LLC for RRY Publications, +1-212-845-4272,
wendy.lau@russopartnersllc.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.